Title:
ANTI-CD40 BINDING MOLECULES HAVING ENGINEERED FC DOMAINS AND THERAPEUTIC USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/065409
Kind Code:
A8
Abstract:
The disclosure provides CD40-binding molecules comprising engineered human IgG domains, for example, human IgG1, IgG2, and IgG4 variants having mutations in the hinge domain, which exhibit altered binding activity to one or more Fey receptors. Also described herein are methods for selectively activating or inhibiting immune responses in a subject using the CD40-binding molecules.
More Like This:
Inventors:
WU YI (CN)
WANG JIEYI (US)
WANG JIEYI (US)
Application Number:
PCT/IB2019/001135
Publication Date:
June 17, 2021
Filing Date:
September 27, 2019
Export Citation:
Assignee:
LYVGEN BIOPHARMA CO LTD (CN)
LYVGEN BIOPHARMA SUZHOU CO LTD (CN)
LYVGEN BIOPHARMA SUZHOU CO LTD (CN)
International Classes:
C07K19/00; A61K38/17; A61K39/395; A61P37/00; C07K16/28; C12N5/10; C12N15/13; C12N15/62; C12N15/63
Attorney, Agent or Firm:
CHEN, Yahua (US)
Download PDF:
Previous Patent: SULFOMALEIMIDE-BASED LINKERS AND CORRESPONDING CONJUGATES
Next Patent: DISCOVERY OF INTERNET-OF-THINGS RESOURCES
Next Patent: DISCOVERY OF INTERNET-OF-THINGS RESOURCES